Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with different glucose metabolism status

Objectives Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. He...

Full description

Saved in:
Bibliographic Details
Published inJournal of endocrinological investigation Vol. 44; no. 4; pp. 781 - 790
Main Authors Zhang, K., Zhu, H., Wang, L., Yang, H., Pan, H., Gong, F.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.04.2021
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1720-8386
0391-4097
1720-8386
DOI10.1007/s40618-020-01372-9

Cover

Abstract Objectives Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations. Methods A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits. Results Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P  < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P  = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P  = 0.003). Conclusion GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations.
AbstractList ObjectivesGlypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations.MethodsA total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits.ResultsSerum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003).ConclusionGPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations.
Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations.OBJECTIVESGlypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations.A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits.METHODSA total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits.Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003).RESULTSSerum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003).GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations.CONCLUSIONGPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations.
Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations. A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits. Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003). GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations.
Objectives Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations. Methods A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits. Results Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P  < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P  = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P  = 0.003). Conclusion GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations.
Author Yang, H.
Gong, F.
Zhang, K.
Pan, H.
Wang, L.
Zhu, H.
Author_xml – sequence: 1
  givenname: K.
  surname: Zhang
  fullname: Zhang, K.
  organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Department of Endocrinology, The First Hospital of Shijiazhuang City
– sequence: 2
  givenname: H.
  surname: Zhu
  fullname: Zhu, H.
  organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
– sequence: 3
  givenname: L.
  surname: Wang
  fullname: Wang, L.
  organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
– sequence: 4
  givenname: H.
  surname: Yang
  fullname: Yang, H.
  organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
– sequence: 5
  givenname: H.
  orcidid: 0000-0003-2413-0646
  surname: Pan
  fullname: Pan, H.
  email: panhui20111111@163.com
  organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
– sequence: 6
  givenname: F.
  surname: Gong
  fullname: Gong, F.
  email: fygong@sina.com
  organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32816247$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1TAQhiNURC_wAiyQJTZsAr4ldpaoUECqxAJYR44z6fGRYwePAzqPx5vVh5SLuujKHvv7Z0Yz_3l1EmKAqnrO6GtGqXqDkrZM15TTmjKheN09qs6YKqEWuj35735anSPuKRVKaPWkOhVcs5ZLdVb9-gJpncmNPyzOmiCJCeMxshEPftlFXHYmu_HgXYjocvQ1LmDd5CzZfqN3i0Eg74iHH-CRmATEIEbrTIaR_HR5R8zollig7BBXIC7gWhKSBOgwm2CPTyQOUBBchz3YjJtwdNMECUIuPa32mGKGbIZSFGdSpHnFp9XjyXiEZ3fnRfXt6v3Xy4_19ecPny7fXtdWqCbXspXGMkk15UPH2mYYZSPa1rKulaCHlpWBTJJraQU3xnS0Gc1IeTeBAmm1EBfVqy3vkuL3FTD3s0ML3psAccWeS9GoRlHOC_ryHrqPawqlu0J1XaePayjUiztqHWYY-yW52aRD_2c5BeAbYFNETDD9RRjtjw7oNwf0xQH9bwf0XRHpeyLrypxcDDkZ5x-Wik2KpU64gfSv7QdUtziNyg4
CitedBy_id crossref_primary_10_1016_j_clinbiochem_2023_110675
crossref_primary_10_1186_s40035_023_00341_5
crossref_primary_10_1002_jcp_31041
crossref_primary_10_1186_s43042_024_00572_9
crossref_primary_10_3389_fendo_2022_822221
crossref_primary_10_2147_PGPM_S463608
crossref_primary_10_3389_fonc_2022_1045995
crossref_primary_10_1016_j_ijcard_2022_08_018
crossref_primary_10_1080_10495398_2024_2374328
crossref_primary_10_1038_s41598_022_14306_7
crossref_primary_10_1161_ATVBAHA_124_321686
crossref_primary_10_1016_j_atherosclerosis_2022_02_015
Cites_doi 10.1016/j.metabol.2008.11.021
10.1006/mgme.2001.3287
10.2337/dc13-0520
10.2337/db16-1167
10.1002/j.1460-2075.1994.tb06438.x
10.1002/hep.23116
10.1210/jcem-72-1-96
10.1016/j.metabol.2003.09.004
10.1126/science.2443973
10.3390/nu7115475
10.1210/jc.2012-4297
10.1111/jdi.12071
10.1007/s00018-007-7471-6
10.1056/NEJMra1011035
10.1182/blood.V83.8.2115.2115
10.1073/pnas.0601752103
10.1210/jc.2006-0075
10.1053/j.gastro.2007.04.068
10.1007/s00125-016-4024-2
10.1172/jci114142
10.1210/jc.2017-00047
10.1152/ajpendo.00319.2018
10.2337/db06-0263
10.1210/jc.2014-2018
10.1210/jc.2016-1376
10.2337/db11-1395
10.2337/dc13-0800
10.2337/diacare.26.12.3320
10.2337/dc18-S002
ContentType Journal Article
Copyright Italian Society of Endocrinology (SIE) 2020
Italian Society of Endocrinology (SIE) 2020.
Copyright_xml – notice: Italian Society of Endocrinology (SIE) 2020
– notice: Italian Society of Endocrinology (SIE) 2020.
DBID AAYXX
CITATION
NPM
K9.
NAPCQ
7X8
DOI 10.1007/s40618-020-01372-9
DatabaseName CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1720-8386
EndPage 790
ExternalDocumentID 32816247
10_1007_s40618_020_01372_9
Genre Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: No. 81673184; No. 81370898
  funderid: http://dx.doi.org/10.13039/501100001809
– fundername: National Key Program of Clinical Science
  grantid: WBYZ2011-873
– fundername: Natural Science Foundation of Beijing Municipality
  grantid: No. 7182130
  funderid: http://dx.doi.org/10.13039/501100004826
– fundername: Natural Science Foundation of Beijing Municipality
  grantid: No. 7182130
– fundername: National Natural Science Foundation of China
  grantid: No. 81370898
– fundername: National Natural Science Foundation of China
  grantid: No. 81673184
GroupedDBID ---
-EM
.GJ
0R~
203
4.4
406
53G
5GY
5RE
8RF
8YF
96X
AACDK
AAEWM
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAZMS
ABAKF
ABDZT
ABECU
ABFTV
ABHLI
ABIPD
ABJNI
ABJOX
ABKCH
ABMQK
ABPLI
ABQBU
ABTEG
ABTKH
ABTMW
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACKNC
ACMLO
ACOKC
ACPIV
ACPRK
ACUDM
ACZOJ
ADHHG
ADINQ
ADJJI
ADKNI
ADKPE
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEODN
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AFBBN
AFQWF
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHSBF
AI.
AIAKS
AIGIU
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKLTO
AKMHD
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
ASPBG
AUKKA
AVWKF
AXYYD
AZFZN
BGNMA
CSCUP
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
ESBYG
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FYJPI
GGCAI
GGRSB
GJIRD
GQ7
GRRUI
HG6
HRMNR
I0C
IKXTQ
IMOTQ
ITM
IWAJR
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
NU0
O93
O9G
O9J
P2P
PT4
RHV
RLLFE
ROL
RSV
SCLPG
SDE
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
TSG
U9L
UG4
UOJIU
UTJUX
UZXMN
VFIZW
VH1
W48
Z7U
Z83
Z87
ZGI
ZMTXR
ZOVNA
ZXP
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
NPM
ABRTQ
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c375t-464ac140802b9165bd45366c1964e8b61162f4284c32aaa905dad029fe7e4c833
IEDL.DBID AGYKE
ISSN 1720-8386
0391-4097
IngestDate Thu Sep 04 19:41:05 EDT 2025
Fri Jul 25 10:02:57 EDT 2025
Thu Apr 03 06:56:35 EDT 2025
Tue Jul 01 02:10:49 EDT 2025
Thu Apr 24 23:07:52 EDT 2025
Fri Feb 21 02:48:56 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Obesity
Adipose tissue insulin resistance (adipo-IR)
Glypican4 (GPC4)
Adiponectin (ADP)
Glycosylphosphatidylinositol-specific phospholipase D (GPLD1)
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-464ac140802b9165bd45366c1964e8b61162f4284c32aaa905dad029fe7e4c833
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2413-0646
PMID 32816247
PQID 2499987387
PQPubID 2043718
PageCount 10
ParticipantIDs proquest_miscellaneous_2435757022
proquest_journals_2499987387
pubmed_primary_32816247
crossref_primary_10_1007_s40618_020_01372_9
crossref_citationtrail_10_1007_s40618_020_01372_9
springer_journals_10_1007_s40618_020_01372_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-04-01
PublicationDateYYYYMMDD 2021-04-01
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Italy
– name: Heidelberg
PublicationSubtitle Official Journal of Italian Society of Endocrinology (SIE)
PublicationTitle Journal of endocrinological investigation
PublicationTitleAbbrev J Endocrinol Invest
PublicationTitleAlternate J Endocrinol Invest
PublicationYear 2021
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Shulman (CR4) 2014; 371
Mahendran, Cederberg, Vangipurapu, Kangas, Soininen, Kuusisto, Uusitupa, Ala-Korpela, Laakso (CR28) 2013; 36
Scherer (CR7) 2006; 55
von Toerne, Huth, de Las Heras Gala, Kronenberg, Herder, Koenig, Meisinger, Rathmann, Waldenberger, Roden, Peters, Thorand, Hauck (CR20) 2016; 59
Ussar, Bezy, Bluher, Kahn (CR11) 2012; 61
Groop, Saloranta, Shank, Bonadonna, Ferrannini, DeFronzo (CR25) 1991; 72
Saponaro, Gaggini, Carli, Gastaldelli (CR1) 2015; 7
Zhu, Pan, Cui, Wang, Wang, Li, Yang, Gong (CR13) 2014; 99
Raikwar, Bowen-Deeg, Du, Low, Deeg (CR17) 2010; 59
Gastaldelli, Harrison, Belfort-Aguilar, Hardies, Balas, Schenker, Cusi (CR6) 2009; 50
Chalasani, Vuppalanchi, Raikwar, Deeg (CR21) 2006; 91
Gastaldelli, Cusi, Pettiti, Hardies, Miyazaki, Berria, Buzzigoli, Sironi, Cersosimo, Ferrannini, Defronzo (CR26) 2007; 133
Masuda, Fujishima, Maeda, Tsugawa-Shimizu, Nakamura, Tanaka, Obata, Fukuda, Nagao, Kita, Nishizawa, Shimomura (CR15) 2019; 316
Fico, Maina, Dono (CR10) 2011; 68
Metz, Brunner, Choi-Muira, Nguyen, Gabrilove, Caras, Altszuler, Rifkin, Wilson, Davitz (CR14) 1994; 13
Gastaldelli, Gaggini, DeFronzo (CR3) 2017; 66
Kurtz, Fineberg, Considine, Deeg (CR19) 2004; 53
Sondergaard, Espinosa De Ycaza, Morgan-Bathke, Jensen (CR5) 2017; 102
Hershkop, Besor, Santoro, Pierpont, Caprio, Weiss (CR9) 2016; 101
Tamori, Kasuga (CR8) 2013; 4
Yoo, Hwang, Cho, Hong, Choi, Hwang, Kim, Bluher, Youn, Baik, Choi (CR29) 2013; 98
Schofield, Stephens, Hurel, Bell, deSouza, Rademacher (CR18) 2002; 75
Brunner, Metz, Nguyen, Gabrilove, Patel, Davitz, Rifkin, Wilson (CR22) 1994; 83
Ascaso, Pardo, Real, Lorente, Priego, Carmena (CR23) 2003; 26
Groop, Bonadonna, DelPrato, Ratheiser, Zyck, Ferrannini, DeFronzo (CR2) 1989; 84
CR24
Gesta, Bluher, Yamamoto, Norris, Berndt, Kralisch, Boucher, Lewis, Kahn (CR12) 2006; 103
Davitz, Hereld, Shak, Krakow, Englund, Nussenzweig (CR16) 1987; 238
Defronzo, Tripathy, Schwenke, Banerji, Bray, Buchanan, Clement, Henry, Kitabchi, Mudaliar, Ratner, Stentz, Musi, Reaven, Gastaldelli (CR27) 2013; 36
S Ussar (1372_CR11) 2012; 61
C von Toerne (1372_CR20) 2016; 59
LC Groop (1372_CR2) 1989; 84
RA Defronzo (1372_CR27) 2013; 36
A Gastaldelli (1372_CR6) 2009; 50
Y Tamori (1372_CR8) 2013; 4
G Brunner (1372_CR22) 1994; 83
CN Metz (1372_CR14) 1994; 13
S Masuda (1372_CR15) 2019; 316
NS Raikwar (1372_CR17) 2010; 59
HJ Yoo (1372_CR29) 2013; 98
PE Scherer (1372_CR7) 2006; 55
C Saponaro (1372_CR1) 2015; 7
GI Shulman (1372_CR4) 2014; 371
MA Davitz (1372_CR16) 1987; 238
TA Kurtz (1372_CR19) 2004; 53
HJ Zhu (1372_CR13) 2014; 99
N Chalasani (1372_CR21) 2006; 91
E Sondergaard (1372_CR5) 2017; 102
1372_CR24
JN Schofield (1372_CR18) 2002; 75
LC Groop (1372_CR25) 1991; 72
JF Ascaso (1372_CR23) 2003; 26
K Hershkop (1372_CR9) 2016; 101
S Gesta (1372_CR12) 2006; 103
A Gastaldelli (1372_CR26) 2007; 133
Y Mahendran (1372_CR28) 2013; 36
A Gastaldelli (1372_CR3) 2017; 66
A Fico (1372_CR10) 2011; 68
References_xml – volume: 59
  start-page: 1413
  issue: 10
  year: 2010
  end-page: 1420
  ident: CR17
  article-title: Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2008.11.021
– volume: 75
  start-page: 154
  issue: 2
  year: 2002
  end-page: 161
  ident: CR18
  article-title: Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats
  publication-title: Mol Genet Metab
  doi: 10.1006/mgme.2001.3287
– volume: 36
  start-page: 3607
  issue: 11
  year: 2013
  end-page: 3612
  ident: CR27
  article-title: Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk
  publication-title: Diabetes Care
  doi: 10.2337/dc13-0520
– volume: 66
  start-page: 815
  issue: 4
  year: 2017
  end-page: 822
  ident: CR3
  article-title: Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio Metabolism Study
  publication-title: Diabetes
  doi: 10.2337/db16-1167
– volume: 13
  start-page: 1741
  issue: 7
  year: 1994
  end-page: 1751
  ident: CR14
  article-title: Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D
  publication-title: EMBO J
  doi: 10.1002/j.1460-2075.1994.tb06438.x
– volume: 50
  start-page: 1087
  issue: 4
  year: 2009
  end-page: 1093
  ident: CR6
  article-title: Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
  publication-title: Hepatology (Baltimore, MD)
  doi: 10.1002/hep.23116
– volume: 72
  start-page: 96
  issue: 1
  year: 1991
  end-page: 107
  ident: CR25
  article-title: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem-72-1-96
– volume: 53
  start-page: 138
  issue: 2
  year: 2004
  end-page: 139
  ident: CR19
  article-title: Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2003.09.004
– volume: 238
  start-page: 81
  issue: 4823
  year: 1987
  end-page: 84
  ident: CR16
  article-title: A glycan-phosphatidylinositol-specific phospholipase D in human serum
  publication-title: Science (New York, NY)
  doi: 10.1126/science.2443973
– volume: 7
  start-page: 9453
  issue: 11
  year: 2015
  end-page: 9474
  ident: CR1
  article-title: The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis
  publication-title: Nutrients
  doi: 10.3390/nu7115475
– volume: 98
  start-page: 2897
  issue: 7
  year: 2013
  end-page: 2901
  ident: CR29
  article-title: Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-4297
– volume: 4
  start-page: 250
  issue: 3
  year: 2013
  end-page: 251
  ident: CR8
  article-title: Glypican-4 is a new comer of adipokines working as insulin sensitizer
  publication-title: J Diabetes Invest
  doi: 10.1111/jdi.12071
– volume: 68
  start-page: 923
  issue: 6
  year: 2011
  end-page: 929
  ident: CR10
  article-title: Fine-tuning of cell signaling by glypicans
  publication-title: Cell Mol Life Sci CMLS
  doi: 10.1007/s00018-007-7471-6
– volume: 371
  start-page: 1131
  issue: 12
  year: 2014
  end-page: 1141
  ident: CR4
  article-title: Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1011035
– volume: 83
  start-page: 2115
  issue: 8
  year: 1994
  end-page: 2125
  ident: CR22
  article-title: An endogenous glycosylphosphatidylinositol-specific phospholipase D releases basic fibroblast growth factor-heparan sulfate proteoglycan complexes from human bone marrow cultures
  publication-title: Blood
  doi: 10.1182/blood.V83.8.2115.2115
– volume: 103
  start-page: 6676
  issue: 17
  year: 2006
  end-page: 6681
  ident: CR12
  article-title: Evidence for a role of developmental genes in the origin of obesity and body fat distribution
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0601752103
– volume: 91
  start-page: 2279
  issue: 6
  year: 2006
  end-page: 2285
  ident: CR21
  article-title: Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic fatty liver disease: a preliminary study
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2006-0075
– volume: 133
  start-page: 496
  issue: 2
  year: 2007
  end-page: 506
  ident: CR26
  article-title: Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2007.04.068
– volume: 59
  start-page: 1882
  issue: 9
  year: 2016
  end-page: 1892
  ident: CR20
  article-title: MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study
  publication-title: Diabetologia
  doi: 10.1007/s00125-016-4024-2
– volume: 84
  start-page: 205
  issue: 1
  year: 1989
  end-page: 213
  ident: CR2
  article-title: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance
  publication-title: J Clin Investig
  doi: 10.1172/jci114142
– volume: 102
  start-page: 1193
  issue: 4
  year: 2017
  end-page: 1199
  ident: CR5
  article-title: How to measure adipose tissue insulin sensitivity
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2017-00047
– volume: 316
  start-page: E239
  issue: 2
  year: 2019
  end-page: E250
  ident: CR15
  article-title: Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00319.2018
– volume: 55
  start-page: 1537
  issue: 6
  year: 2006
  end-page: 1545
  ident: CR7
  article-title: Adipose tissue: from lipid storage compartment to endocrine organ
  publication-title: Diabetes
  doi: 10.2337/db06-0263
– volume: 99
  start-page: E2697
  issue: 12
  year: 2014
  end-page: 2701
  ident: CR13
  article-title: The changes of serum glypican4 in obese patients with different glucose metabolism status
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-2018
– volume: 101
  start-page: 2423
  issue: 6
  year: 2016
  end-page: 2431
  ident: CR9
  article-title: Adipose insulin resistance in obese adolescents across the spectrum of glucose tolerance
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2016-1376
– volume: 61
  start-page: 2289
  issue: 9
  year: 2012
  end-page: 2298
  ident: CR11
  article-title: Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine
  publication-title: Diabetes
  doi: 10.2337/db11-1395
– volume: 36
  start-page: 3732
  issue: 11
  year: 2013
  end-page: 3738
  ident: CR28
  article-title: Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men
  publication-title: Diabetes Care
  doi: 10.2337/dc13-0800
– ident: CR24
– volume: 26
  start-page: 3320
  issue: 12
  year: 2003
  end-page: 3325
  ident: CR23
  article-title: Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism
  publication-title: Diabetes Care
  doi: 10.2337/diacare.26.12.3320
– volume: 36
  start-page: 3607
  issue: 11
  year: 2013
  ident: 1372_CR27
  publication-title: Diabetes Care
  doi: 10.2337/dc13-0520
– volume: 133
  start-page: 496
  issue: 2
  year: 2007
  ident: 1372_CR26
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2007.04.068
– volume: 102
  start-page: 1193
  issue: 4
  year: 2017
  ident: 1372_CR5
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2017-00047
– volume: 99
  start-page: E2697
  issue: 12
  year: 2014
  ident: 1372_CR13
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-2018
– volume: 103
  start-page: 6676
  issue: 17
  year: 2006
  ident: 1372_CR12
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0601752103
– volume: 66
  start-page: 815
  issue: 4
  year: 2017
  ident: 1372_CR3
  publication-title: Diabetes
  doi: 10.2337/db16-1167
– volume: 371
  start-page: 1131
  issue: 12
  year: 2014
  ident: 1372_CR4
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1011035
– volume: 59
  start-page: 1413
  issue: 10
  year: 2010
  ident: 1372_CR17
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2008.11.021
– volume: 75
  start-page: 154
  issue: 2
  year: 2002
  ident: 1372_CR18
  publication-title: Mol Genet Metab
  doi: 10.1006/mgme.2001.3287
– volume: 50
  start-page: 1087
  issue: 4
  year: 2009
  ident: 1372_CR6
  publication-title: Hepatology (Baltimore, MD)
  doi: 10.1002/hep.23116
– volume: 7
  start-page: 9453
  issue: 11
  year: 2015
  ident: 1372_CR1
  publication-title: Nutrients
  doi: 10.3390/nu7115475
– volume: 13
  start-page: 1741
  issue: 7
  year: 1994
  ident: 1372_CR14
  publication-title: EMBO J
  doi: 10.1002/j.1460-2075.1994.tb06438.x
– volume: 61
  start-page: 2289
  issue: 9
  year: 2012
  ident: 1372_CR11
  publication-title: Diabetes
  doi: 10.2337/db11-1395
– volume: 55
  start-page: 1537
  issue: 6
  year: 2006
  ident: 1372_CR7
  publication-title: Diabetes
  doi: 10.2337/db06-0263
– volume: 98
  start-page: 2897
  issue: 7
  year: 2013
  ident: 1372_CR29
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-4297
– volume: 4
  start-page: 250
  issue: 3
  year: 2013
  ident: 1372_CR8
  publication-title: J Diabetes Invest
  doi: 10.1111/jdi.12071
– volume: 36
  start-page: 3732
  issue: 11
  year: 2013
  ident: 1372_CR28
  publication-title: Diabetes Care
  doi: 10.2337/dc13-0800
– volume: 101
  start-page: 2423
  issue: 6
  year: 2016
  ident: 1372_CR9
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2016-1376
– ident: 1372_CR24
  doi: 10.2337/dc18-S002
– volume: 68
  start-page: 923
  issue: 6
  year: 2011
  ident: 1372_CR10
  publication-title: Cell Mol Life Sci CMLS
  doi: 10.1007/s00018-007-7471-6
– volume: 26
  start-page: 3320
  issue: 12
  year: 2003
  ident: 1372_CR23
  publication-title: Diabetes Care
  doi: 10.2337/diacare.26.12.3320
– volume: 91
  start-page: 2279
  issue: 6
  year: 2006
  ident: 1372_CR21
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2006-0075
– volume: 84
  start-page: 205
  issue: 1
  year: 1989
  ident: 1372_CR2
  publication-title: J Clin Investig
  doi: 10.1172/jci114142
– volume: 59
  start-page: 1882
  issue: 9
  year: 2016
  ident: 1372_CR20
  publication-title: Diabetologia
  doi: 10.1007/s00125-016-4024-2
– volume: 83
  start-page: 2115
  issue: 8
  year: 1994
  ident: 1372_CR22
  publication-title: Blood
  doi: 10.1182/blood.V83.8.2115.2115
– volume: 53
  start-page: 138
  issue: 2
  year: 2004
  ident: 1372_CR19
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2003.09.004
– volume: 316
  start-page: E239
  issue: 2
  year: 2019
  ident: 1372_CR15
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00319.2018
– volume: 72
  start-page: 96
  issue: 1
  year: 1991
  ident: 1372_CR25
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem-72-1-96
– volume: 238
  start-page: 81
  issue: 4823
  year: 1987
  ident: 1372_CR16
  publication-title: Science (New York, NY)
  doi: 10.1126/science.2443973
SSID ssj0037387
Score 2.370045
Snippet Objectives Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific...
Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific...
ObjectivesGlypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 781
SubjectTerms Adiponectin
Adipose tissue
Diabetes mellitus (non-insulin dependent)
Endocrinology
Glucose
Glucose metabolism
Glucose tolerance
Glycosylphosphatidylinositol
Heparan sulfate proteoglycans
Hyperinsulinemia
Insulin
Insulin resistance
Internal Medicine
Lipids
Medicine
Medicine & Public Health
Metabolic Diseases
Metabolism
Obesity
Original Article
Phospholipase D
Title Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with different glucose metabolism status
URI https://link.springer.com/article/10.1007/s40618-020-01372-9
https://www.ncbi.nlm.nih.gov/pubmed/32816247
https://www.proquest.com/docview/2499987387
https://www.proquest.com/docview/2435757022
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgKyEuvB8LpTISN0iV2E7iHFvoUoHaEyuVU-RXYEU2iZrksPw7_hkziRMEBaQeE48TJzOeh_3NmJBXkhVS20IGMKlVIKyMA_ASeAC2r-CFDY0bTm84O09O1-LDRXzhk8LaCe0-bUkOmnpOdkPTIwMMd7BMHguym2QvjmQmF2Tv6P3njyeTBsZiPalPkPl7z9-N0BXP8squ6GBsVnfJehrmiDH5dth3-tB8_6OC43W_4x65471PejSKy31yw1UPyK0zv7_-kPwA1dFv6Zdy16B6FFRVFq9M3e4Qxd42X4GTdgfvRbBXXQaYqYloIzq21uWmAbtI39ES0UgtVZeOKi8CzlJc9qXKbpoaiLqB6dTD4SkE_ujMghTCLVprByRtr3GhqB07Tqe5dNQj7enWdSDF5abdUkyN6ttHZL06-fT2NPCHPASGp3EXiEQoA1GeDJkGVzXWVsQ8SQwWCnNSJ1GUsAJiJGE4U0plYWyVDVlWuNQJIzl_TBZVXbmnhMbGpJhrbJTmQqeJdhCBR5mKi8SGhWNLEk1cz42vgI4HcZT5XLt54E0OvMkH3uTZkrye-zRj_Y__Uu9PwpR7XdDmDINKiTK5JC_nZpjFuDWjKlf3SMPBb07BoVqSJ6MQzq_jTMI_END7zSRQvx7-77E8ux75c3KbIVxnACXtk0V32bsX4G91-gCm1-r4-PzAT7Ofdg8n3Q
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgK0EvvCkLBYzEDVJlbSdxjhW0LLTbU1cqp8ivwIrsJmqSw_Lv-GfMJE4QFJB6TDxOnMx4HvY3Y0JeS5ZLbXMZwKRWgbAyCsBL4AHYvpznNjSuO71hcRbPl-LTRXThk8LqAe0-bEl2mnpMdkPTIwMMd7BMHgvSm2RHQAweTsjO4YfPJ0eDBsZiPYlPkPl7z9-N0BXP8squaGdsju-S5TDMHmPy7aBt9IH5_kcFx-t-xz1yx3uf9LAXl_vkhts8ILcWfn_9IfkBqqNd0y_FtkL1KKjaWLwyZb1FFHtdfQVO2i28F8FeZRFgpiaijWjfWharCuwifU8LRCPVVF06qrwIOEtx2Zcqu6pKIGo6plMPh6cQ-KMzC1IIt2ipHZDUrcaForrvOJzm0lCPtKdr14AUF6t6TTE1qq0fkeXx0fm7eeAPeQgMT6ImELFQBqI8GTINrmqkrYh4HBssFOakjmezmOUQIwnDmVIqDSOrbMjS3CVOGMn5YzLZlBv3hNDImARzjY3SXOgk1g4i8Fmqojy2Ye7YlMwGrmfGV0DHgziKbKzd3PEmA95kHW-ydErejH2qvv7Hf6n3B2HKvC6oM4ZBpUSZnJJXYzPMYtyaURtXtkjDwW9OwKGakr1eCMfXcSbhHwjo_XYQqF8P__dYnl6P_CW5PT9fnGanH89OnpFdhtCdDqC0TybNZeueg-_V6Bd-qv0E_j8pPg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgK1VceFMWChiJG7jN2s7rWNEuhdKKA5XKKfIrsCKbRJvksPw7_hkzibM8CkiI4ybjrHf92fNN_M2YkGcJzxNt84TBpFZM2iRkwBIEA9-Xi9wGxvWnN5yeRcfn8s1FePFDFn-vdh-3JIecBqzSVLb7tc33N4lv6IYShqEPlszjLL1KtmQA5H9Ctg5efTg5GldjLNwT-2SZ37f82SFdYpmXdkh7xzO_QdTY5UFv8nmva_We-fJLNcf_-U03yXXPSunBAKNb5Iorb5PtU7_vfod8hSWlW9KPxbrGZVNSVVr8ZKpmjer2pv4EI2zX0AcUgVUFwwxOVCHR4W5VLGrwl_SQFqhSaqhaOao8NJyl-DqYKruoKzBqezBQL5OnK9cgyQV0wiVaaQcmTafxBVIzNBxPeWmpV-DTpWsB3cWiWVJMmeqau-R8fvT-5THzhz8wI-KwZTKSykD0lwRcA4UNtZWhiCKDBcRcoqPZLOI5xE7SCK6USoPQKhvwNHexkyYR4h6ZlFXp7hMaGhNjDrJRWkgdR9pBZD5LVZhHNsgdn5LZiIDM-MroeEBHkW1qOvdjk8HYZP3YZOmUPN-0qYe6IH-13h2Blfk1osk4BpsJ4nNKnm5uw-zGLRtVuqpDGwF8OgaiNSU7AyA3Xyd4Av-BhNYvRnB9f_if-_Lg38yfkO13h_Ps7euzk4fkGkdFT69b2iWTdtW5R0DJWv3Yz7pvX2oyIg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+glypican4+and+glycosylphosphatidylinositol-specific+phospholipase+D+levels+are+associated+with+adipose+tissue+insulin+resistance+in+obese+subjects+with+different+glucose+metabolism+status&rft.jtitle=Journal+of+endocrinological+investigation&rft.au=Zhang%2C+K.&rft.au=Zhu%2C+H.&rft.au=Wang%2C+L.&rft.au=Yang%2C+H.&rft.date=2021-04-01&rft.issn=1720-8386&rft.eissn=1720-8386&rft.volume=44&rft.issue=4&rft.spage=781&rft.epage=790&rft_id=info:doi/10.1007%2Fs40618-020-01372-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s40618_020_01372_9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1720-8386&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1720-8386&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1720-8386&client=summon